Company

Our work

Voronoi develops novel TPD (Target protein degraders) and kinase inhibitors with the aim to treat intractable and rare diseases. We are developing competitive therapies based on deep understanding of diseases and innovative technologies.

Company

About VORONOI

Voronoi is a bio-venture with global competitiveness in the field of Kinase Genotype-directed therapy.

People

Meet the experts

Our experts and the management bring to the team years of experience and expertise in various fields.